Related Experiment Video

Updated: May 6, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.3K

Research Article: FKBP4-HSP90 Interaction in Colorectal Cancer: A Novel Therapeutic Target

Yuvasri Golivi1, Santosh Kumar Behera2, Sujatha Peela3

  • 1Banasthali Vidyapith.

Critical Reviews in Oncogenesis
|November 23, 2025
PubMed

Insights

FKBP4 is overexpressed in colorectal cancer (CRC) and strongly interacts with heat shock protein 90 (HSP90). Targeting this FKBP4-HSP90 interaction may offer a new therapeutic strategy for CRC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Colorectal cancer (CRC) progression involves key molecular pathways like heat shock protein 90 (HSP90), PI3K/AKT, TP53, and mismatch repair (MMR).
  • Identifying novel biomarkers and therapeutic targets is crucial for improving CRC patient outcomes.

Purpose of the Study:

  • To investigate the role of FKBP4 in colorectal cancer.
  • To explore the association between FKBP4 and HSP90 in CRC.
  • To evaluate the FKBP4-HSP90 interaction as a potential therapeutic target for CRC.

Main Methods:

  • Analysis of FKBP4 expression in CRC patient samples at transcript and translational levels.
  • STRING network analysis to identify associations between FKBP4 and other proteins.
  • Utilizing TCGA CRC patient data to assess correlations between FKBP4 and HSP90.
  • Employing molecular docking, dynamics simulations, and hydrogen bond analysis to confirm FKBP4-HSP90 interactions.

Main Results:

  • FKBP4 was found to be overexpressed in CRC patient samples.
  • A strong association and positive correlation were identified between FKBP4 and HSP90.
  • Molecular simulations confirmed a significant interaction between FKBP4 and HSP90, highlighting its role in CRC cell survival and progression.

Conclusions:

  • FKBP4 may serve as a predictive biomarker for CRC diagnosis.
  • The FKBP4-HSP90 complex plays a critical role in colorectal cancer progression.
  • Disrupting the FKBP4-HSP90 interaction presents a promising therapeutic strategy for CRC treatment.

More Related Videos

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.8K
Studies of Chaperone-Cochaperone Interactions using Homogenous Bead-Based Assay06:51

Studies of Chaperone-Cochaperone Interactions using Homogenous Bead-Based Assay

Published on: July 21, 2021

3.2K

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129